TY - JOUR
T1 - Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases
T2 - Definitions, frequency and pharmacological aspects
AU - Allez, Matthieu
AU - Karmiris, Konstantinos
AU - Louis, Edouard
AU - Van Assche, Gert
AU - Ben-Horin, Shomron
AU - Klein, Amir
AU - Van der Woude, Janneke
AU - Baert, Filip
AU - Eliakim, Rami
AU - Katsanos, Konstantinos
AU - Brynskov, Jørn
AU - Steinwurz, Flavio
AU - Danese, Silvio
AU - Vermeire, Severine
AU - Teillaud, Jean Luc
AU - Lémann, Marc
AU - Chowers, Yehuda
N1 - Funding Information:
M Allez has received speaker fees from Abbott, Schering-Plough and UCB. K Karmiris has received speaker fees from MSD and Abbott. E Louis has received research grants form Astra Zeneca and Schering Plough, speaker fees from Ferring, Abbott, Schering Plough, Centocor, and consulting fees from Abbott, Ferring, UCB, Schering Plough and MSD. G Van Assche has received research support and/or honoraria from Abbott, Schering-Plough, Centocor, UCB Pharma. S Ben-Horin has served as consultant for Schering-Plough and Abbot Laboratories. F Baert served on the speakers’ bureau of MSD and Abbott Laboratories, and received a research grant from Abbott. F Steinwurz received honoraria from MSD and served as speaker for MSD and Abbott. S Danese received consulting fees from Shering Plough, Abbott Laboratories, AstraZeneca, UCB Pharma, Actelion, Danone, Ferring, and participated in continuing medical education events sponsored by Abbott Laboratories, Ferring, UCB Pharma, Shering Plough, Giuliani Pharma, Chiesi. S Vermeire has received Grants/Research Support from UCB; as served as consultant for Astra-Zeneca, Ferring and Pfizer; as speakers Bureau for Shering-Plough, Abbott, Ferring and UCB; and as advisory Committee for Shire and Ferring. M Lémann has received consulting fees from Abbott, UCB, Scherring Plough, Shire, Ferring, Astra, BMS, PDL, Novartis, Sanofi Synthelabo, Centocor, Elan, Millenium, Shire, Ferring, Novartis and PDL. Y Chowers has received consulting fees from Abbott and Shering Plough.
PY - 2010/10
Y1 - 2010/10
N2 - The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.
AB - The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.
KW - Anti-TNF therapy
KW - Crohn's disease
KW - Immunogenicity
KW - Inflammatory bowel diseases
KW - Pharmacology
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=77957309991&partnerID=8YFLogxK
U2 - 10.1016/j.crohns.2010.04.004
DO - 10.1016/j.crohns.2010.04.004
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:77957309991
SN - 1873-9946
VL - 4
SP - 355
EP - 366
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
IS - 4
ER -